Medicaid
AHA urges Congress to reject reductions to the Medicaid program that would not only strip access to health care from some of the most vulnerable populations but also destabilize hospitals and health systems, leading to a loss of services that would impact patients and communities nationwide.
The AHA calls on Congress to reject changes to states’ use of provider taxes, which help fund their Medicaid programs.
AHA urges Congress to reject reductions to hospitals’ Medicaid payments.
A per capita cap to federal financing of the Medicaid program would be a fundamental change to how the program is financed. It would put untenable fiscal pressures on state governments, leading to Medicaid coverage, enrollment and provider reimbursement cuts.
The Medicaid program is the largest single source of health care coverage in the United States, covering nearly half of all children, many low-income elderly and disabled individuals, and working adults in low-wage jobs. With the passage of the One Big Beautiful Bill Act (P.L. 119-21), Congress…
The White House Office of Management and Budget Jan. 29 rescinded a memo it issued two days earlier directing federal agencies to temporarily pause federal grants, loans and other financial assistance programs implicated by President Trump’s recent executive orders.
Section 340B of the Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for patients in vulnerable communities.
The White House Office of Management and Budget (OMB) late last night issued a memo directing federal agencies to temporarily pause federal grants, loans and other financial assistance programs implicated by President Trump’s recent executive orders.
The White House Office of Management and Budget late Jan. 27 issued a memo directing federal agencies to temporarily pause federal grants, loans and other financial assistance programs implicated by President Trump’s recent executive orders.
The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of Lyfgenia) and Vertex Pharmaceuticals (manufacturer of Casgevy) will participate in its Cell and Gene Therapy Access Model.